Heena Sharma Blog

  AstraZeneca Plc’s Covid-19 vaccine manufacturing partner in Southeast Asia has missed a delivery target in Thailand and shipments to other countries in the region have been delayed, the latest setback for a shot that was meant to be the backbone of the global inoculation effort. Thailand was slated to receive and administer 6 million AstraZeneca vaccine doses in June but health authorities this week said they would be distributing only about 3.5 million of those shots this month. Pledging to still give out 6 million doses as planned, officials appear to be making up the shortfall with millions of shots from China’s Sinovac Biotech Ltd. Shipments of shots made by Siam Bioscience -- AstraZeneca’s Bangkok-based partner, which has links to the Thai royal family -- to Malaysia and the Philippines have also been delayed, though both countries say they don’t expect to be waiting for too long. The situation comes on top of delivery problems at India’s Serum Institute of India Ltd., a

India ranks third globally in terms of the number of family-owned businesses with 111 companies of $839 billion total market capitalisation, followed closely after China with 159 firms and the United States with 121 firms, says a report. According to the 'Credit Suisse Family 1000 in 2018' report, published by the Credit Suisse Research Institute (CSRI), in terms of the number of family-owned businesses, within the non-Japan Asian region, China, India and Hong Kong dominate the list. These three jurisdictions together comprise around 65 per cent of the non-Japan Asian section of the CSRI's database, and has a combined market capitalisation of $2.85 trillion (or 71 per cent) of the market share. Korea came in fourth place, with 43 companies ($ 434.1 billion market capitalisation), followed by Indonesia, Malaysia, the Philippines and Thailand, each with 26 companies. Read Complete Article